BB&T Securities LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 1.5% during the third quarter, Holdings Channel reports. The fund owned 129,222 shares of the medical research company’s stock after selling 2,011 shares during the period. BB&T Securities LLC’s holdings in Amgen were worth $21,555,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in shares of Amgen during the second quarter worth approximately $383,036,000. FMR LLC raised its stake in shares of Amgen by 4.0% in the second quarter. FMR LLC now owns 32,386,936 shares of the medical research company’s stock worth $4,927,672,000 after buying an additional 1,259,875 shares during the period. Vanguard Group Inc. raised its stake in shares of Amgen by 1.5% in the second quarter. Vanguard Group Inc. now owns 46,679,076 shares of the medical research company’s stock worth $7,102,222,000 after buying an additional 673,247 shares during the period. Pictet Asset Management Ltd. increased its position in Amgen by 71.7% in the second quarter. Pictet Asset Management Ltd. now owns 1,460,956 shares of the medical research company’s stock worth $230,758,000 after buying an additional 610,106 shares in the last quarter. Finally, Numeric Investors LLC increased its position in Amgen by 58.2% in the second quarter. Numeric Investors LLC now owns 1,620,496 shares of the medical research company’s stock worth $246,558,000 after buying an additional 596,160 shares in the last quarter. Institutional investors own 79.01% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded up 2.80% on Friday, hitting $157.26. The stock had a trading volume of 429,811 shares. The company’s 50 day moving average is $150.60 and its 200-day moving average is $159.41. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $176.85. The stock has a market cap of $116.99 billion, a P/E ratio of 15.74 and a beta of 1.14.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.23. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.72 earnings per share. Analysts forecast that Amgen Inc. will post $11.55 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 8th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $1.15 per share. This is a boost from Amgen’s previous quarterly dividend of $1.00. The ex-dividend date of this dividend is Monday, February 13th. This represents a $4.60 annualized dividend and a yield of 3.01%. Amgen’s dividend payout ratio (DPR) is 39.92%.
AMGN has been the topic of a number of research analyst reports. Mizuho initiated coverage on shares of Amgen in a report on Monday, November 7th. They set a “buy” rating and a $164.00 price objective on the stock. RBC Capital Markets set a $190.00 price target on Amgen and gave the company a “buy” rating in a research report on Wednesday, January 4th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $182.34 price target on the stock in a research report on Monday, October 24th. Credit Suisse Group cut Amgen from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $200.00 to $180.00 in a research report on Tuesday, December 20th. They noted that the move was a valuation call. Finally, Chardan Capital upgraded Amgen from a “sell” rating to a “neutral” rating in a research report on Tuesday, December 13th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $179.48.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).